STEMI与NSTEMI非罪犯易损斑块及预后:PROSPECT II亚研究
PROSPECT II亚研究纳入898例近期心肌梗死患者,比较STEMI与NSTEMI患者非罪犯病变中高危易损斑块的患病率及长期预后。结果显示,患者水平高危斑块患病率两组相似,非罪犯病变相关及全部主要不良心血管事件4年发生率亦无显著差异,支持两类心梗后非罪犯病变采用相似血运重建策略。
要点
- STEMI与NSTEMI患者非罪犯病变中高危斑块的患者水平患病率相似。
- 非罪犯病变相关MACE的4年发生率两组无显著差异。
- 结果支持STEMI与NSTEMI非罪犯病变采用相似血运重建策略。
核心结论
- STEMI与NSTEMI患者高危易损斑块的患者水平患病率相当,非罪犯病变相关及全部MACE长期发生率亦相似。
研究设计与样本
- PROSPECT II为多中心前瞻性自然病史研究,2014至2017年纳入近期心肌梗死并成功PCI闭塞病变的患者,行三支冠脉造影联合近红外光谱与血管内超声。
- 共898例患者,STEMI组199例(22.2%)含849个非罪犯病变,NSTEMI组699例(77.8%)含2784个非罪犯病变,中位随访3.7年。
主要发现
- 病变水平双特征高危非阻塞性非罪犯斑块患病率STEMI略高于NSTEMI(12.8% versus 10.1%;P=0.03)。
- 患者水平双特征高危斑块患病率STEMI与NSTEMI相似(38.8% versus 32.7%;P=0.11)。
- 非罪犯病变相关MACE的4年发生率STEMI与NSTEMI相似(8.6% versus 7.8%;HR 1.02 [95%CI 0.57-1.81];P=0.95)。
- 全部MACE的4年发生率两组亦相似(14.2% versus 13.0%;HR 1.06 [95%CI 0.68-1.64];P=0.80)。
关键数值与推荐
- 双特征高危斑块定义为斑块负荷≥70%且任意4 mm段最大脂质核心负荷指数≥324.7。
- 非罪犯病变中位长度STEMI为17.4 mm(IQR 16.3-18.5),NSTEMI为17.7 mm(IQR 17.1-18.4),P=0.63。
- 中位最小管腔面积STEMI为5.5 mm²(IQR 5.3-5.7),NSTEMI为5.5 mm²(IQR 5.3-5.6),P=0.99。
- 至少1个病变满足斑块负荷≥70%的患者比例STEMI 63.3% versus NSTEMI 57.8%(P=0.16)。
- 至少1个病变满足最大脂质核心负荷指数≥324.7的患者比例STEMI 63.3% versus NSTEMI 57.6%(P=0.15)。
临床怎么用
- STEMI与NSTEMI患者罪犯病变处理后,非罪犯病变可采用相似的血运重建策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical guidelines recommend different revascularization strategies for nonculprit lesions in patients with ST-segment-elevation myocardial infarction (STEMI) versus non-STEMI (NSTEMI). Whether the prevalence of untreated high-risk vulnerable plaques differs in STEMI and NSTEMI and affects their outcomes is unknown. METHODS: In PROSPECT II (Providing Regional Observations to Study Predictors of Events in the Coronary Tree II), a multicenter, prospective natural history study, patients with recent myocardial infarction underwent 3-vessel coronary angiography with coregistered near-infrared spectroscopy and intravascular ultrasound after successful percutaneous coronary intervention of obstructive lesions from 2014 through 2017. Two-feature high-risk plaques were defined as those with both plaque burden ≥70% and maximum lipid core burden index over any 4-mm segment ≥324.7. The primary end point was major adverse cardiovascular events arising from untreated nonculprit lesions during a median 3.7-year follow-up. RESULTS: Of 898 patients, 199 (22.2%) with 849 nonculprit lesions had STEMI and 699 (77.8%) with 2784 nonculprit lesions had NSTEMI. By intravascular ultrasound, the median nonculprit lesion length was 17.4 mm (interquartile range, 16.3-18.5) in STEMI and 17.7 mm (interquartile range, 17.1-18.4) in NSTEMI (P=0.63), and the median minimal lumen area was 5.5 mm2 (interquartile range, 5.3-5.7 mm2) in STEMI and 5.5 mm2 (interquartile range, 5.3-5.6 mm2) in NSTEMI (P=0.99). At the lesion level, the prevalence of 2-feature high-risk nonobstructive nonculprit plaques was slightly higher in patients with STEMI than in patients with NSTEMI (12.8% versus 10.1%; P=0.03). At the patient level, however, the prevalence of 2-feature high-risk plaques was similar in STEMI versus NSTEMI (38.8% versus 32.7%; P=0.11). The prevalence of patients with 1 or more lesions meeting at least 1 high-risk plaque criterion was also similar (plaque burden ≥70%, 63.3% versus 57.8% [P=0.16]; maximum lipid core burden index over any 4-mm segment ≥324.7, 63.3% versus 57.6% [P=0.15]). The 4-year rates of nonculprit lesion-related major adverse cardiovascular events were similar in STEMI versus NSTEMI (8.6% versus 7.8%; hazard ratio, 1.02 [95% CI, 0.57-1.81]; P=0.95), as were the rates of all major adverse cardiovascular events (14.2% versus 13.0%; hazard ratio, 1.06 [95% CI, 0.68-1.64]; P=0.80). CONCLUSIONS: In the PROSPECT II study, the per-patient prevalence of high-risk vulnerable plaques was comparable in STEMI versus NSTEMI, as was the overall long-term incidence of nonculprit lesion-related and all major adverse cardiovascular events. These results support a similar revascularization strategy for nonculprit lesions in patients with STEMI or NSTEMI after culprit lesion management. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02171065.
引用
- Thrane, Maeng, Maehara, et al. Nonculprit Vulnerable Plaques and Prognosis in Myocardial Infarction With Versus Without ST-Segment Elevation: A PROSPECT II Substudy. Circulation. 2025. PMID: 40549845. doi:10.1161/CIRCULATIONAHA.124.071980
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。